Phase II Randomized Study of Ixabepilone Versus Observation in Patients With Significant Residual Disease After Neoadjuvant Systemic Therapy for HER2-Negative Breast Cancer

Gonzalez-Angulo Ana M.; Lei Xiudong; Alvarez Richardo H.; Green Majorie C.; Murray James L.; Valero Vicente; Koenig Kimberly B.; Ibrahim Nuhad K.; Litton Jennifer K.; Nair Lakshmy; Krishnamurthy Savitri; Hortobagyi Gabriel N.; Meric-Bemstarn Funda

首页> 外文期刊>Clinical breast cancer >Phase II Randomized Study of Ixabepilone Versus Observation in Patients With Significant Residual Disease After Neoadjuvant Systemic Therapy for HER2-Negative Breast Cancer

【24h】

Phase II Randomized Study of Ixabepilone Versus Observation in Patients With Significant Residual Disease After Neoadjuvant Systemic Therapy for HER2-Negative Breast Cancer

机译：新辅助系统治疗HER2阴性乳腺癌后有重大残留病患者的伊沙贝比隆与观察结果的II期随机研究

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

We conducted a phase II study in patients with RCB II or III randomized to ixabepilone versus observation. Adjuvant ixabepilone after neoadjuvant systemic therapy and radiation was difficult to administer because of AEs and did not change the presence of circulating tumor cells or affect survival outcomes.

机译：我们对随机分配给ixabepilone与观察值的RCB II或III的患者进行了II期研究。新辅助全身治疗和放疗后的ixabepilone辅助药物由于AE而难以给药，并且不会改变循环肿瘤细胞的存在或影响生存结果。

著录项

来源
《Clinical breast cancer》 |2015年第5期|共7页
作者
Gonzalez-Angulo Ana M.; Lei Xiudong; Alvarez Richardo H.; Green Majorie C.; Murray James L.; Valero Vicente; Koenig Kimberly B.; Ibrahim Nuhad K.; Litton Jennifer K.; Nair Lakshmy; Krishnamurthy Savitri; Hortobagyi Gabriel N.; Meric-Bemstarn Funda;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类肿瘤学;
关键词
Chemoresistance; Circulating tumor cells; Ixabepilone; Neoadjuvant systemic therapy; Residual disease;

机译：化学耐药性;循环肿瘤细胞;伊沙贝比隆;新辅助全身治疗;残留疾病;

相似文献

外文文献
中文文献
专利

1. 来自一项艾日布林联合吉西他滨对比紫杉醇联合吉西他滨作为HER2阴性转移性乳腺癌的一线化疗的II期、多中心、随机试验的包含神经病变相关量表的生活质量结果:韩国癌症研究组试验(KCSG BR13-11) [J] . Ji-Yeon Kim, Young-Hyuck Im, Tae-Yong Kim, 癌症（英文版） . 2019,第008期
2. Phase II Randomized Study of Ixabepilone Versus Observation in Patients With Significant Residual Disease After Neoadjuvant Systemic Therapy for HER2-Negative Breast Cancer [J] . Gonzalez-Angulo Ana M., Lei Xiudong, Alvarez Richardo H., Clinical breast cancer . 2015,第5期

机译：新辅助系统治疗HER2阴性乳腺癌后有重大残留病患者的伊沙贝比隆与观察结果的II期随机研究
3. A Randomized Phase II Study of Sequential Eribulin Versus Paclitaxel Followed by FAC/FEC as Neoadjuvant Therapy in Patients with Operable HER2-Negative Breast Cancer [J] . Bora Lim, Simona F. Shaitelman, Gary J. Whitman, The oncologist . 2021,第2期

机译：序贯叶蛋白的随机期II研究与紫杉醇相比，随后是可操作Her2阴性乳腺癌患者Neoadjuvant治疗的FAC / FEC
4. A phase II trial of ixabepilone and cyclophosphamide as neoadjuvant therapy for patients with HER2-negative breast cancer: correlation of pathologic complete response with the 21-gene recurrence score [J] . Yardley Denise A., Peacock Nancy W., Shastry Mythili, Breast cancer research and treatment. . 2015,第2期

机译：依沙贝比隆和环磷酰胺作为HER2阴性乳腺癌患者的新辅助疗法的II期临床试验：病理完全缓解与21基因复发评分的相关性
5. Breast MRI radiomics for the pre-treatment prediction of response to neoadjuvant chemotherapy in node-positive breast cancer patients [C] . Karen Drukker, Iman El-Bawab, Alexandra Edwards, SPIE Conference on Computer-Aided Diagnosis . 2019

机译：乳腺MRI辐射射清，用于节点阳性乳腺癌患者对新辅助化疗的反应预处理预测
6. Supportive Care for Patients with Breast Cancer by Using an Interactive App During Neoadjuvant Chemotherapy: A Randomized Controlled Trial [D] . Fjell, Maria. 2021

机译：通过在Neoadjuvant化疗期间使用互动性应用的乳腺癌患者的支持性护理：随机对照试验
7. Phase II randomized study of ixabepilone vs. observation in patients with significant residual disease after neoadjuvant systemic therapy for HER2-negative breast cancer [O] . Ana M Gonzalez-Angulo, Xiudong Lei, Richardo H Alvarez, -1

机译：ixabepilone的II期随机研究与HER2阴性乳腺癌新辅助全身治疗后有明显残留疾病的患者的观察
8. A Phase II Study of Adjuvant Chemotherapy of Tegafur–Uracil for Patients with Breast Cancer with HER2-negative Pathologic Residual Invasive Disease After Neoadjuvant Chemotherapy [O] . SATORU TANAKA, MITSUHIKO IWAMOTO, KOSEI KIMURA, 2016

机译：Neoadjuvant化疗后Her2阴性病理残留侵入性乳腺癌患者TEGAFUR-Uracil辅助化疗的II期研究

Phase II Randomized Study of Ixabepilone Versus Observation in Patients With Significant Residual Disease After Neoadjuvant Systemic Therapy for HER2-Negative Breast Cancer

摘要

著录项

相似文献

相关主题

期刊订阅